에 대한 최신 뉴스 aTyr Pharma (NASDAQ:ATYR) 주식

ATYR PHARMA INC

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

WIIM

SSRM

SSR Mining shares are trading lower after the company announced its operations at Seabee have been temporarily suspended.

<p><strong>AnaptysBio, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.</p>
<p>In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.</p>
<p>Furthermore, responses were then durable for at least two months off the drug.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a></strong></p>
<p>Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.</p>
<p>All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.</p>
<p>CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.</p>
<p>The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.</p>
<p>As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.</p>
<p>Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.</p>
<p>HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;</p>
<p>Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.</p>
<p><strong>HC Wainwright Highlights Competitor Datasets</strong></p>
<p>Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared <strong>AbbVie Inc&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs <strong>Bristol Myers Squibb&nbsp;&amp; Co&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.</p>
<p>In contrast, <strong>Eli Lilly And Co</strong>&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.</p>
<p><strong>Johnson &amp; Johnson</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.</p>
<p><strong>Price Action:</strong> ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Biotech

News

Upgrades

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ABBV

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

<p><strong>Peloton Interactive, Inc.</strong> shares are trading higher Wednesday. On Tuesday, a report suggested the company is launching a resale market for used bikes and treadmills.</p>
<p><strong>The Details: </strong>According to <a href="https://www.cnbc.com/2025/06/03/peloton-launching-resale-market-for-used-bikes-treadmills.html">CNBC</a>, Peloton has rolled out Repowered, a platform that lets users list their used equipment and apparel, with pricing guidance provided by a generative artificial intelligence tool.</p>
<p>Sellers will receive 70% of the sale price, with the remainder shared between Peloton and its resale partner Archive. They will also get a discount toward new equipment. Buyers will benefit from a lower activation fee, which the company said is dropping from $95 to $45 for used products. </p>
<p>Peloton said buyers will be able to view the equipment's history on the listing and can choose to have it delivered for an additional fee.</p>
<p>The company also said that as of last summer, connected fitness subscriptions from customers who purchased hardware through secondary channels were up 16% year-over-year.</p>
<p>Repowered launched as a beta version in New York City, Boston and Washington D.C., with plans to expand across the United States in the coming months.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a></strong></p>
<p><strong>PTON Price Action: </strong>At the time of writing, Peloton shares are trading 11.2% higher at $7.40, according to data from Benzinga Pro.</p>
<p><em>Image: via Shutterstock</em></p>


PTON

Peloton Stock Is Climbing Higher Wednesday: What's Going On?

<p><a href="https://www.wsj.com/business/media/meta-seeks-hollywood-deals-for-new-virtual-reality-headset-ef3db942">https://www.wsj.com/business/media/meta-seeks-hollywood-deals-for-new-virtual-reality-headset-ef3db942</a></p>


'Meta Seeks Hollywood Deals for New Virtual-Reality Headset'- WSJ

<p><strong>Wells Fargo &amp; Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading higher Wednesday following its announcement that it&#8217;s no longer subject to asset growth restrictions that were <a href="https://www.benzinga.com//node/45758069">imposed in 2018</a>.</p>
<p><strong>What To Know: </strong>On Tuesday, Wells Fargo said the Federal Reserve lifted the asset cap that had been in place since 2018, a penalty tied to the bank's fake-account scandal, according to the <a href="https://apnews.com/article/wells-fargo-federal-reserve-sales-practices-assets-e1d79548c0da446320c441e88de3eea4">Associated Press</a>.</p>
<p>The Federal Reserve&#8217;s decision to lift the asset cap marks a pivotal milestone in our journey to transform Wells Fargo. We are a different and far stronger company today because of the work we&#8217;ve done,&#8221; said Wells Fargo CEO <strong>Charlie Scharf</strong>.&nbsp;</p>
<p>The fake-accounts scandal, which erupted in 2018, stemmed from a high-pressure sales culture that led employees to open millions of unauthorized accounts in an effort to meet aggressive performance goals.</p>
<p>Since taking the helm in 2019, Scharf has worked to convince regulators that Wells Fargo has overhauled its practices and addressed longstanding compliance failures.</p>
<p>&#8220;In addition, we have changed and simplified our business mix, and we have transformed the management team and how we run the company. We have been methodically investing in the company&#8217;s future while improving our financial results and profile,&#8221; Scharf added.</p>
<p>&#8220;We are excited to continue to move forward with plans to further increase returns and growth in a deliberate manner supported by the processes and cultural changes we have made.&#8221;</p>
<p><strong>See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">Pump.fun&#8217;s $1B Token Plan Risks Undermining Solana DeFi, Fueling Meme Coin Scams, Experts Warn</a></strong></p>
<p><strong>WFC Price Action:</strong> At the time of publication, Wells Fargo stock is trading 0.41% higher at $75.96, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjk9-eNmtiNAxWxg4kEHSKNIm4QFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.</p>
<p><em>Image: via Shutterstock</em></p>


Wells Fargo Stock Is Trading Higher Wednesday: What's Going On?

<p><a href="https://x.com/pulte/status/1930323713154789718">https://x.com/pulte/status/1930323713154789718</a></p>


U.S. Director Of Federal Housing FHFA Pulte Posts On X "I am meeting with the Equifax CEO today, it should be an interesting meeting. I also had a great meeting with the National Association of Realtors and much more"

<p>Roth Capital  analyst George Kelly   reiterates Mama's Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) with a Buy and raises the price target from $9 to $10.</p>


Price Target

Reiteration

MAMA

Roth Capital Reiterates Buy on Mama's Creations, Raises Price Target to $10

<p><figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/06/2025-06-04_08h29_43.png" alt="" /></figure></p>
<p><em>To gain an edge, this is what you need to know today.</em></p>
<h4 class="wp-block-heading"><strong>Stock Market Magnet</strong></h4>
<p>Please <a href="https://thearorareport.com/stock-market-chart-analysis-stock-market-magnet-trump-budget-spy-mc-06042025">click here</a> for an enlarged chart of <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).</p>
<p>Note the following:</p>
<ul class="wp-block-list">
<li>The chart shows that the pull of zone 1 as the stock market's magnet is very strong.</li>
<li>The chart shows that RSI has now become barely overbought.&nbsp; This indicates that there is room for the stock market to move to zone 1, but the stock market can also pull back due to overbought conditions.</li>
<li>Elon Musk is calling President Trump's budget a "disgusting abomination."&nbsp; Musk says, "Congress is making America bankrupt." Musk claims that President Trump's "One Big Beautiful Bill" will massively increase the budget deficit to $2.5T.<br />
<ul class="wp-block-list">
<li>The momo crowd buys <strong>Tesla Inc</strong> (TSLA) stock on every comment from Musk.  How is the momo crowd reacting to Musk's comment about President Trump's budget?  The momo crowd is aggressively buying stocks as the pull of the zone 1 magnet in the stock market is much stronger than Musk's influence.</li>
<li>Prudent investors should pay attention to Musk's comment about President Trump's budget.&nbsp; After all, Musk spent $250M of his own money to get Trump elected and countless hours in Washington on DOGE to help President Trump.</li>
</ul>
</li>
<li>President Trump said, "I like President XI of China, always have, and always will, but he is VERY TOUGH, AND EXTREMELY HARD TO MAKE A DEAL WITH!!!"<br />
<ul class="wp-block-list">
<li>How does the momo crowd react to President Trump's statement?&nbsp; The momo crowd is buying stocks because President Trump likes President Xi, and they are ignoring President Trump saying that President Xi is extremely hard to make a deal with.</li>
<li>Prudent investors should not ignore half of President Trump's statement.</li>
</ul>
</li>
<li><strong>Automatic Data Processing Inc</strong> (ADP) is the largest private payroll processor in the country.   ADP data poured cold water on all the bullishness.  ADP showed employment much weaker than expected.  ADP Employment Change came at 37K vs. 115K consensus.<br />
<ul class="wp-block-list">
<li>Weak ADP data brought quick selling to the stock market, but as of this writing, the momo crowd is aggressively buying the shallow dip caused by the ADP data.</li>
</ul>
</li>
<li>ADP data comes after JOLTS data.&nbsp; JOLTS came at 7.391M vs. 7.2M prior.&nbsp; JOLTS data contributed to yesterday's stock market rally.</li>
<li>Initial jobless claims will be released tomorrow at 8:30am ET and the official jobs report will be released Friday at 8:30am ET.</li>
<li>ISM Services was released today at 10am ET.  ISM Services data can cause major moves in the markets.  ISM Services data is a leading indicator and carries heavy weight in the adaptive <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model</a> with a long proven track record with inputs in <a href="https://thearorareport.com/unique-zyx-asset-allocation-4/">10 categories</a>.</li>
<li>The Fed's Beige Book will be released today at 2pm ET and may be market moving.</li>
<li>There has been significant Fed speak:<br />
<ul class="wp-block-list">
<li>Dallas Fed President Logan said the Fed should focus on forward looking policy that is prepared for a high inflation era.</li>
<li>Fed Governor Cook warned of increasing uncertainty with trade policy potentially pressuring inflation and jobs.</li>
<li>Atlanta Fed President Bostic indicated room for one rate cut in 2025.</li>
</ul>
</li>
<li>For the AI trade,  earnings from <strong>Broadcom Inc</strong> (AVGO) are important.  Earnings will be released after market close.</li>
<li>Also important are earnings from <strong>Lululemon Athletica Inc</strong> (LULU) as it will give a glimpse into the state of the higher end consumer as well as lower end consumers who purchase Lululemon as a status symbol.</li>
</ul>
<h4 class="wp-block-heading"><strong>Magnificent Seven Money Flows</strong></h4>
<p>In the early trade, money flows are positive in <strong>Meta Platforms Inc</strong> (META) and <strong>NVIDIA Corp</strong> (NVDA).</p>
<p>In the early trade, money flows are neutral in <strong>Amazon.com, Inc.</strong> (AMZN), <strong>Alphabet Inc Class C</strong> (GOOG), <strong>Microsoft Corp </strong>(MSFT), and TSLA.</p>
<p>In the early trade, money flows are negative in <strong>Apple Inc </strong>(AAPL).</p>
<p>In the early trade, money flows are like a yoyo in S&amp;P 500 ETF (SPY) and <strong>Invesco QQQ Trust Series 1</strong> (QQQ).</p>
<h4 class="wp-block-heading"><strong>Momo Crowd And Smart Money In Stocks</strong></h4>
<p>Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is <strong>SPDR Gold Trust</strong> (GLD).  The most popular ETF for silver is <strong>iShares Silver Trust </strong>(SLV).  The most popular ETF for oil is <strong>United States Oil ETF</strong> (USO).</p>
<h4 class="wp-block-heading"><strong>Oil</strong></h4>
<p>API crude inventories came at a draw of 3.3M barrels vs. a consensus of a draw of 0.9M barrels.&nbsp; This data is bearish for oil, but new politics will trump any data.</p>
<h4 class="wp-block-heading"><strong>Bitcoin</strong></h4>
<p><strong>Bitcoin</strong> is range bound.</p>
<h4 class="wp-block-heading"><strong>Arora Protection Band And What To Do Now</strong></h4>
<p>It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.</p>
<p>Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.</p>
<p>You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.</p>
<p>A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.</p>
<p><strong>It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; </strong>When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.</p>
<h4 class="wp-block-heading"><strong>Traditional 60/40 Portfolio</strong></h4>
<p>Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.</p>
<p>Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.</p>
<p><strong>The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever </strong><a href="https://thearorareport.com/generate-wealth-newsletter-benzinga"><strong>Generate Wealth Newsletter</strong></a><strong>.</strong></p>


Equities

Long Ideas

Market Summary

Broad U.S. Equity ETFs

Opinion

Markets

Pull Of Stock Market Magnet Stronger Than Musk Calling Trump's Budget A "Disgusting Abomination"

<p><a href="https://www.federalreserve.gov/monetarypolicy/beigebook202505-summary.htm">https://www.federalreserve.gov/monetarypolicy/beigebook202505-summary.htm</a></p>


Macro Economic Events

Macro Notification

Econ #s

Economics

Fed Beige Book: This Report Was Prepared At The Federal Reserve Bank of ST.; Reports Across the Twelve Federal Reserve Districts Indicate That Economic Activity Has Declined Slightly Since the Previous Report; However, a Few District Reports Indicate the Outlook Has Deteriorated While a Few Others Indicate the Outlook Has Improved; Prices Have Increased at a Moderate Pace Since the Previous Report

<p>Citigroup  analyst Paul Lejuez   maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy and lowers the price target from $60 to $55.</p>


Citigroup Maintains Buy on Academy Sports, Lowers Price Target to $55

<p>Roth Capital  analyst Matt Koranda   reiterates Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) with a Buy and raises the price target from $2.5 to $3.</p>


SPWH

Roth Capital Reiterates Buy on Sportsman's Warehouse, Raises Price Target to $3

<p>During the last three months, 15 analysts shared their evaluations of Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Wells Fargo and provided 12-month price targets. The average target is $81.23, accompanied by a high estimate of $90.00 and a low estimate of $73.00. A 0.56% drop is evident in the current average compared to the previous average price target of $81.69. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060099_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Wells Fargo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$78.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Vivek Juneja</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.50</td>
<td>$82.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Wells Fargo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Wells Fargo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Wells Fargo's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Wells Fargo's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WFC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Wells Fargo analyst ratings.</strong></a></p>
<h2>About Wells Fargo</h2>
<p>Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US</p>
<h3>Understanding the Numbers: Wells Fargo's Finances</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Challenges:</strong> Wells Fargo's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-3.42%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Wells Fargo's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>22.91%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Wells Fargo's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.86%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Wells Fargo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.24%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.16</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Wells Fargo Stock

<p>Analysts' ratings for Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.33, a high estimate of $45.00, and a low estimate of $38.00. A 2.06% drop is evident in the current average compared to the previous average price target of $42.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060084_0_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Valvoline among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason English</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Chasen Bender</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Max Rakhlenko</td>
<td>TD Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Valvoline. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Valvoline compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Valvoline's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Valvoline's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VVV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Valvoline analyst ratings.</strong></a></p>
<h2>Discovering Valvoline: A Closer Look</h2>
<p>Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.</p>
<h3>Financial Insights: Valvoline</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Valvoline's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>3.73%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Valvoline's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>9.33%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Valvoline's ROE excels beyond industry benchmarks, reaching <strong>15.72%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Valvoline's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.57%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Valvoline's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>5.51</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Valvoline Stands With Analysts

<p>Deep-pocketed investors have adopted a bullish approach towards Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ISRG usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Intuitive Surgical. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 2 are puts, totaling $132,426, and 10 are calls, amounting to $704,446.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $290.0 and $780.0 for Intuitive Surgical, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Surgical's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Surgical's substantial trades, within a strike price spectrum from $290.0 to $780.0 over the preceding 30 days.</p>
<h3>Intuitive Surgical 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060084_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$280.1</td>
<td>$280.0</td>
<td>$280.0</td>
<td>$290.00</td>
<td>$280.0K</td>
<td align="right">28</td>
<td align="right">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$20.1</td>
<td>$18.4</td>
<td>$19.75</td>
<td>$555.00</td>
<td>$98.7K</td>
<td align="right">4</td>
<td align="right">50</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$49.4</td>
<td>$49.3</td>
<td>$49.3</td>
<td>$560.00</td>
<td>$98.7K</td>
<td align="right">135</td>
<td align="right">21</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$115.2</td>
<td>$112.4</td>
<td>$115.2</td>
<td>$500.00</td>
<td>$57.6K</td>
<td align="right">156</td>
<td align="right">5</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$36.0</td>
<td>$35.1</td>
<td>$36.0</td>
<td>$540.00</td>
<td>$50.4K</td>
<td align="right">98</td>
<td align="right">16</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.</p>
<p>In light of the recent options history for Intuitive Surgical, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Intuitive Surgical Standing Right Now?</h3>
<ul>
<li>With a volume of 509,158, the price of ISRG is up 1.03% at $557.56. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $650.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Intuitive Surgical with a target price of $650. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuitive Surgical with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

ISRG

What the Options Market Tells Us About Intuitive Surgical

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Wells Fargo</strong>.</p>
<p>Looking at options history for Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) we detected 51 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 19% with bearish.</p>
<p>From the overall spotted trades, 11 are puts, for a total amount of $816,327 and 40, calls, for a total amount of $4,010,392.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $90.0 for Wells Fargo over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Wells Fargo stands at 5713.74, with a total volume reaching 94,086.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Wells Fargo, situated within the strike price corridor from $40.0 to $90.0, throughout the last 30 days.</p>
<h3>Wells Fargo Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060079_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.4</td>
<td>$25.35</td>
<td>$25.35</td>
<td>$55.00</td>
<td>$593.2K</td>
<td>26.6K</td>
<td>239</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$13.1</td>
<td>$13.05</td>
<td>$13.05</td>
<td>$65.00</td>
<td>$391.5K</td>
<td>4.6K</td>
<td>699</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$13.55</td>
<td>$12.85</td>
<td>$13.49</td>
<td>$65.00</td>
<td>$371.1K</td>
<td>4.6K</td>
<td>277</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$33.7</td>
<td>$33.55</td>
<td>$33.62</td>
<td>$45.00</td>
<td>$336.1K</td>
<td>5.7K</td>
<td>100</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.14</td>
<td>$1.12</td>
<td>$1.13</td>
<td>$67.50</td>
<td>$203.1K</td>
<td>1.8K</td>
<td>8.9K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Wells Fargo</h3>
<p>Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US</p>
<p>In light of the recent options history for Wells Fargo, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Wells Fargo</h3>
<ul>
<li>Trading volume stands at 19,874,529, with WFC's price up by 0.5%, positioned at $76.03.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>Expert Opinions on Wells Fargo</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $87.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Wells Fargo, maintaining a target price of $87.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Wells Fargo, maintaining a target price of $88.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Wells Fargo with a target price of $90.<br />
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $85. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Wells Fargo with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Looking At Wells Fargo's Recent Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on Merck &amp; Co. Our analysis of options history for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed 30 unusual trades.</p>
<p>Delving into the details, we found 60% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $413,444, and 22 were calls, valued at $1,845,337.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $110.0 for Merck &amp; Co over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck &amp; Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck &amp; Co's significant trades, within a strike price range of $40.0 to $110.0, over the past month.</p>
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060074_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.5</td>
<td>$2.47</td>
<td>$2.5</td>
<td>$85.00</td>
<td>$159.2K</td>
<td>4.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.77</td>
<td>$2.72</td>
<td>$2.77</td>
<td>$80.00</td>
<td>$145.4K</td>
<td>3.9K</td>
<td>631</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$12.15</td>
<td>$11.9</td>
<td>$12.15</td>
<td>$75.00</td>
<td>$143.3K</td>
<td>650</td>
<td>196</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.86</td>
<td>$2.83</td>
<td>$2.86</td>
<td>$80.00</td>
<td>$143.0K</td>
<td>3.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$38.75</td>
<td>$38.6</td>
<td>$38.6</td>
<td>$40.00</td>
<td>$115.8K</td>
<td>0</td>
<td>60</td>
</tr>
</tbody>
</table>
</p>
<h3>About Merck &amp; Co</h3>
<p>Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.</p>
<p>In light of the recent options history for Merck &amp; Co, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a volume of 6,348,843, the price of MRK is up 1.92% at $78.62. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 55 days.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $84.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup has revised its rating downward to Neutral, adjusting the price target to $84. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Merck & Co

<p>Ratings for Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Patterson-UTI Energy, revealing an average target of $8.28, a high estimate of $12.00, and a low estimate of $6.50. A decline of 19.22% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060073_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Patterson-UTI Energy among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$6.50</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Patterson-UTI Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Patterson-UTI Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Patterson-UTI Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Patterson-UTI Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PTEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Patterson-UTI Energy analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Patterson-UTI Energy</h2>
<p>Patterson-UTI Energy Inc is one of the substantial land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. The company operates under three reportable business segments: (i) drilling services, (ii) completion services, and (iii) drilling products. It also provides directional drilling services and tool rental services in united states onshore oil and gas basins.</p>
<h3>Patterson-UTI Energy: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Patterson-UTI Energy's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-15.22%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Patterson-UTI Energy's net margin excels beyond industry benchmarks, reaching <strong>0.08%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Patterson-UTI Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.03%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Patterson-UTI Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.02%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Patterson-UTI Energy's debt-to-equity ratio is below the industry average. With a ratio of <b>0.38</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PTEN

Beyond The Numbers: 9 Analysts Discuss Patterson-UTI Energy Stock

<p>Analysts' ratings for CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for CME Group, revealing an average target of $276.38, a high estimate of $305.00, and a low estimate of $211.00. Observing a 4.33% increase, the current average has risen from the previous average price target of $264.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060053_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive CME Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Mike Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$304.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$273.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$211.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$283.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$279.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$301.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$279.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$269.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$219.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$287.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CME Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CME Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of CME Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into CME Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CME Group analyst ratings.</strong></a></p>
<h2>Delving into CME Group's Background</h2>
<p>Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.</p>
<h3>CME Group: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> CME Group's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>10.38%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> CME Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>57.49%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CME Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.53%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> CME Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.64%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.13</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


13 Analysts Assess CME Group: What You Need To Know

<p>Ratings for 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.36, with a high estimate of $18.00 and a low estimate of $6.50. Experiencing a 18.74% decline, the current average is now lower than the previous average price target of $15.21. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060045_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of 10x Genomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$6.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to 10x Genomics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 10x Genomics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for 10x Genomics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of 10x Genomics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TXG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on 10x Genomics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About 10x Genomics</h2>
<p>10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).</p>
<h3>10x Genomics: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> 10x Genomics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>9.84%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> 10x Genomics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-22.18%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> 10x Genomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-4.85%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> 10x Genomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> 10x Genomics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.11</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 7 Analyst Projections For 10x Genomics

<p><strong>Laureate Education's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAUR#NYSE">LAUR</a>) short percent of float has risen 5.88% since its last report. The company recently reported that it has <strong>2.92 million shares sold short</strong>, which is 2.52% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.28 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Laureate Education Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749060029_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Laureate Education has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Laureate Education's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Laureate Education's peer group average for short interest as a percentage of float is 4.39%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

LAUR

Is the Market Bullish or Bearish on Laureate Education?

Press Releases

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Earnings

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Comments

aTyr Pharma

뉴스

에 대한 최신 뉴스 aTyr Pharma (NASDAQ:ATYR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌